Faggioni A, Corradini C, Barile G, Cardi G, Ciarniello V, Venenzoni M, Zompetta C, Maurizi M, Paludetti G, Manzari V
J Cancer Res Clin Oncol. 1985;110(2):157-60. doi: 10.1007/BF00402731.
This paper reports the results of the EBV-specific antibody response in 17 Italian nasopharyngeal carcinoma (NPC) patients, 15 other head and neck tumor patients and 15 normal controls. Nucleic acid hybridization has been performed on the biopsy tissue from 4 of the NPC patients, and EBV-DNA was present in two undifferentiated (WHO 3) tumors, and absent in two samples of the keratinizing (WHO 1) type. EBV serology appears to be specifically related to NPC, more evidently for VCA-IgA and EA-IgG antibodies, and useful as an aid in diagnosis of NPC. However, in order to assess a prognostic value of the above markers, a greater number of patients followed for a longer period of time (at least 5 years) is needed, and is currently being pursued.
本文报告了17例意大利鼻咽癌(NPC)患者、15例其他头颈部肿瘤患者和15例正常对照者的EBV特异性抗体反应结果。对4例NPC患者的活检组织进行了核酸杂交,在2例未分化(WHO 3型)肿瘤中检测到EBV-DNA,而在2例角化型(WHO 1型)样本中未检测到。EBV血清学似乎与NPC有特异性关联,对于VCA-IgA和EA-IgG抗体而言更为明显,并且有助于NPC的诊断。然而,为了评估上述标志物的预后价值,需要对更多患者进行更长时间(至少5年)的随访,目前正在开展此项工作。